Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program.
Oct 7, 2026DOI: 10.1093/cid/ciag271Journal ArticleCID
Written by: Stuart H CohenPaul AllynFelicia C ChowJennifer RatheDeepa D NanayakkaraGerald HutflesTara VijayanEthan A SmithChristopher F SalingDan IlgesHaran T SchlammGeorge R Thompson
Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix ("gepix"), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; non-meningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.
TV
Dr. Tara Vijayan
Infectious Disease · General Infectious DiseaseUniversity of California, Los Angelestarav